AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

March 31, 2026
2 min

The Medicine Maker

1

AstraZeneca is establishing a commercial manufacturing and supply base for cell therapy in Shanghai.
2

The new facility will produce autologous CAR-T therapies for China and other Asian markets.
3

AstraZeneca will support the clinical trials of its BCMA/CD19 dual-target CAR-T candidate, AZD0120.
4

The AstraZeneca Gracell Cell Therapy Innovation Center will focus on early research and regulatory support.
5

AstraZeneca launched a collaboration program to connect Shanghai's biotech sector with UK research networks.

Original Source(s)

The Medicine Maker

AstraZeneca Deepens China Cell Therapy Push

March 31, 2026

Related Content

Frontiers In Oncology

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

by Xinlong Xu, Chang Dong, Jiashuo Guo, Xiaolin Chang, Yu Zhang, Shuting Gou, Liying Xue, Jie Li
April 29, 2026

Dana-Farber

Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma

The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.